Search

At any given time over 1.4 million people worldwide are suffering from infections they got from their health-provider, according to the World Health Organization. Pelias AG, a newly created affiliate of Austrian biotech company Intercell AG, is hoping to raise €15 million to €20 million to make a dent in those numbers.

News Editor Thomas Lau spoke to Florian Schönharting, a partner at the Nordic Biotech, a fund that has invested in Denmark’s Gastrotech BipPharma - a biotechnology company that recently merged with US biotech firm DOR BioPharma. Nordic Biotech, a specialised biotech venture capital fund focusing primarily on Nordic countries and the EU, has invested in Gastrotech since its inception in March 2003.

8.8 per cent: The proportion of GDP that OECD countries spend on health.

Diamonds are the hardest natural substance known to man, and hard to find too. But Russian scientists say they have found a way to make prospecting for the precious mineral much easier.

Cambridge University is tightening its grip on rights to intellectual property generated by staff and students after academics voted overwhelmingly to endorse new plans

On inventive Californians, technology transfer, how to approach the business press, and other insights into R&D management.

Investing in technology that's a few years from commercialisation can be tricky. Lori Valigra finds out how some venture capitalists sort the wheat from the chaff.

A Swiss team has developed a reliable blood test for younger, live cows. Now it is looking for investment to develop a test for Creutzfeldt-Jakob disease in humans.

What are stem cells, what could they do - and why are investors wary of putting their money in them? A lay guide to the technology

With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.

The European Commission's Clinical Trials Directive was meant to make trials more simple. But it looks as if the effect has been to stop many trials taking place at all.

Cambridge University wants rights to the intellectual property generated by its staff. The idea has divided scientists in a university well known for its high-tech spin-outs.

Two New Year's resolutions for the governments around the world that have managed to gum up the economic machinery behind technological development.

A new Swedish company backed by government and business angels aims to create an entire funding ecosystem for young companies until they become ready for venture capital.

Every cloud has its silver lining. So if it wasn't for his daughter's diabetes, Anders Essen-Möller might not have sold his company and started Diamyd Medical AB.

University tech transfer offices should stop trying to do the impossible, says Biofusion CEO David Baynes.